Sands Capital Ventures’s Taysha Gene Therapies TSHA Stock Holding History

Sands Capital Ventures’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.94M	Hold	724,873	–	–	0.8%	21
2026 Q1	$3.24M	Hold	724,873	–	–	0.77%	17
2025 Q4	$3.99M	Hold	724,873	–	–	0.77%	18
2025 Q3	$2.37M	Hold	724,873	–	–	0.52%	18
2025 Q2	$1.67M	Hold	724,873	–	–	0.33%	19
2025 Q1	$1.01M	Hold	724,873	–	–	0.25%	20
2024 Q4	$1.25M	Hold	724,873	–	–	0.27%	19
2024 Q3	$1.46M	Hold	724,873	–	–	0.41%	12
2024 Q2	$1.62M	Hold	724,873	–	–	0.54%	11
2024 Q1	$2.08M	Hold	724,873	–	–	0.5%	10
2023 Q4	$1.28M	Hold	724,873	–	–	0.36%	13
2023 Q3	$2.29M	Hold	724,873	–	–	0.68%	13
2023 Q2	$478K	Hold	724,873	–	–	0.14%	14
2023 Q1	$580K	Hold	724,873	–	–	0.14%	16
2022 Q4	$1.64M	Hold	724,873	–	–	0.45%	15
2022 Q3	$1.4M	Hold	724,873	–	–	0.41%	16
2022 Q2	$2.7M	Hold	724,873	–	–	0.74%	16
2022 Q1	$4.73M	Hold	724,873	–	–	0.99%	13
2021 Q4	$8.45M	Hold	724,873	–	–	1.25%	11
2021 Q3	$13.5M	Buy	+724,873	New	+$13.8M	2.04%	7

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Sands Capital Ventures's TSHA Position: Q2 2026 in Review

Sands Capital Ventures held its Taysha Gene Therapies (TSHA) position steady in Q2 2026 at 724,873 shares worth $4.94M. The position accounts for 0.8% of the portfolio, ranked #21.

Sands Capital Ventures first reported a position in TSHA in Q3 2021 and has held it in 20 quarters since. The position peaked at $13.5M in Q3 2021. 192 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Sands Capital Ventures held 724,873 shares of Taysha Gene Therapies worth $4.94M as of Q2 2026.
Sands Capital Ventures left its Taysha Gene Therapies share count unchanged in Q2 2026.
Taysha Gene Therapies made up 0.8% of Sands Capital Ventures's portfolio in Q2 2026, its #21 holding.
Sands Capital Ventures first reported a position in Taysha Gene Therapies in Q3 2021 and has held it in 20 quarters since.
Sands Capital Ventures's Taysha Gene Therapies position peaked at $13.5M in Q3 2021.
192 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Sands Capital Ventures's 13F filing for Q2 2026, filed 13 Aug 2026.